United Therapeutics Corporation (UTHR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 2 Margin 5 Expansion 5 Platform 2 Financial 4

latest quarter score

Earnings Reports

18
United Therapeutics (UTHR) Q2 2026: Pipeline Advancements Set Stage for Multi-Billion Dollar IPF and PAH Launches
August 05, 2026
23
United Therapeutics (UTHR) Q1 2026: Relenopeg Data Signals Path to $8B+ Revenue Run Rate
May 06, 2026
24
United Therapeutics (UTHR) Q4 2025: Tyvaso DPI Grows 24% as Pipeline Launches Set Up $4B Run Rate
February 25, 2026
22
United Therapeutics (UTHR) Q3 2025: Tyvaso DPI Drives 7% Revenue Growth as IPF Pipeline Accelerates
October 29, 2025
23
United Therapeutics (UTHR) Q2 2025: Tyvaso DPI Grows 22% as Pipeline Catalysts Approach
July 30, 2025
25
United Therapeutics (UTHR) Q1 2025: Tyvaso-Driven 17% Growth Anchors Double-Digit Outlook Amid Pipeline Milestones
July 04, 2025

Browse all companies